Reactivity and immunogenicity of monovalent A/New Jersey/76 influenza virus vaccines in children.
This paper presents the methodology of the multicenter collaborative clinical trials that evaluated monovalent A/New Jersey/76 influenza virus vaccines in healthy children six months to 18 years of age and describes the experience involving 264 children six months to 10 years of age in Omaha, Nebraska. Results indicated that chidren can be safely and effectively immunized with carefully adjusted two-dose regimens that take into account the differences between split-virus and whole-virus vaccines and between the two whole-virsu vaccines.
D000293:Adolescent; D000914:Antibodies, Viral / Q000096:biosynthesis; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000494:pharmacology*; D009515:New Jersey
D000914:Antibodies, Viral; D007252:Influenza Vaccines